Information  X 
Enter a valid email address

EPIC/TIDM matching '68CT'

Date
Time Source
Company
Announcement
25 Apr 2017 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
29 Mar 2017 9:00 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
22 Mar 2017 6:15 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
13 Mar 2017 7:08 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
25 Jan 2017 5:31 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2016
  6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
12 Dec 2016 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
01 Nov 2016 6:15 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer
25 Oct 2016 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
18 Sep 2016 9:00 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients
25 Aug 2016 6:15 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
19 Jul 2016 6:01 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
17 May 2016 4:30 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis
09 May 2016 2:53 pm RNS   Factsheet Novartis Finance S.A (68CT) Publication of a Prospectus
21 Apr 2016 6:01 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth
27 Jan 2016 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations
17 Jan 2016 9:00 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US
04 Nov 2015 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors
27 Oct 2015 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance
23 Oct 2015 12:25 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis
25 Sep 2015 6:15 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis' new heart failure medicine Entresto(TM) recommended by CHMP for EU approval
24 Sep 2015 5:00 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retires
21 Jul 2015 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches
07 Jul 2015 9:33 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization
16 Apr 2015 5:26 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mg
06 Mar 2015 2:10 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz
13 Feb 2015 4:30 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis' heart failure medicine LCZ696 granted FDA priority review
27 Jan 2015 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses
25 Jan 2015 9:23 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis Bexsero® vaccine approved by FDA for the prevention of meningitis B, the leading cause of bacterial meningitis in the US
28 Nov 2014 6:15 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis' heart failure medicine LCZ696 granted...
21 Nov 2014 6:15 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis Cosentyx(TM) receives positive CHMP op...
17 Nov 2014 9:45 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Nine new analyses show Novartis' LCZ696 could c...
28 Oct 2014 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivered solid sales growth with stro...
26 Oct 2014 9:00 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis announces divestiture of influenza vac...
23 Oct 2014 6:15 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis AIN457 (secukinumab) meets primary end...
15 Oct 2014 10:00 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis announces CTL019 data published in NEJ...
08 Oct 2014 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Changes to the Novartis Executive Committee aft...
06 Oct 2014 6:15 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis announces clinical collaboration to ev...
31 Aug 2014 9:00 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis' new heart failure medicine LCZ696 cut...
11 Aug 2014 6:15 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis to showcase heart failure leadership a...
17 Jul 2014 6:01 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis maintained strong innovation momentum ...
18 Jun 2014 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis emphasizes new focused portfolio at it...
15 May 2014 4:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis settles patent litigation on Gleevec&#...
29 Apr 2014 8:30 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis gains FDA approval for Zykadia(TM), fi...
24 Apr 2014 6:01 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivered solid sales and profit growt...
22 Apr 2014 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis announces portfolio transformation, fo...
09 Apr 2014 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis appoints Jeff George as Division Head,...
31 Mar 2014 6:15 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) PARADIGM-HF trial of Novartis' LCZ696 for chron...
27 Mar 2014 9:09 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis to work with FDA on path forward for R...
21 Mar 2014 9:35 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) UK recommends Novartis Bexsero® vaccine fo...
25 Feb 2014 1:06 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis shareholders approve all resolutions p...
17 Feb 2014 6:15 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis expands cancer immunotherapy research ...
29 Jan 2014 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivers strong sales and innovation i...
24 Jan 2014 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis to request re-examination of serelaxin...
22 Nov 2013 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis highlights growth prospects driven by ...
11 Nov 2013 6:05 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis announces divestiture of its blood tra...
22 Oct 2013 6:00 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis delivers strong sales performance in t...
26 Jul 2013 12:44 pm GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis first in class once-daily dual broncho...
17 Jul 2013 6:15 am GNW   Factsheet NOVARTIS AG CHF0.50(REGD) (68CT) Novartis announces final agreement with Dr. Dan...


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t